ReviewBiology2026
Hyperlipidemia Intervention from Medicine-Food Homologous Plants: A Review of Regulatory Status, Processing Techniques, and Lipid-Lowering Mechanisms.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe rising global prevalence of hyperlipidemia is closely linked to current dietary patterns, sparking interest in "medicine-food homology" (MFH) plants as natural resources that provide both nutritional benefits and therapeutic effects. This study reviews MFH plants used to treat hyperlipidemia, incorporating changes in regulatory mechanisms, the impact of processing on bioavailability, and evidence of their lipid-lowering effects.
methodsThis narrative review, supported by a structured literature search, summarizes the practical applications of MFH plant species with both medicinal and edible properties and discusses their bioactive components and lipid-regulating mechanisms.
resultsMFH plants not only contain anti-lipid active ingredients but also have improved bioavailability after processing through processing technology and function through lipid metabolism pathways and the gut-liver axis.
conclusionsThe development and application of MFH plants face several challenges, including incomplete and inconsistent international regulatory frameworks, difficulties in quality control, and limited clinical evidence for lipid-lowering mechanisms. Nevertheless, MFH plants hold promise for development into functional foods or nutraceuticals aimed at supporting lipid regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.